The ASPEN-1 and ASPEN-OLS presentations at AAN this week contain data that have already been released for the most part, so it’s hard to see how these presentations could move the share price materially.
Regarding the FDA acceptance of the Daxi BLA resubmission for filing, the only way that could move the share materially higher is if the FDA were to designate the review as Class-1, which has a 2-month, rather than 6-month, review clock (from the date of the resubmission). However, the nature of the BLA resubmission points to a Class-2 designation, and RVNC itself has acknowledged this.
p.s. Are you back in?
News 
Market Data 
Discover 
